keyword
MENU ▼
Read by QxMD icon Read
search

Crohn's and TNF

keyword
https://www.readbyqxmd.com/read/28067059/il-23-blockade-for-crohn-s-disease-next-generation-of-anti-cytokine-therapy
#1
Federica Furfaro, Daniela Gilardi, Mariangela Allocca, Clelia Cicerone, Carmen Correale, Gionata Fiorino, Silvio Danese
Adaptive immunity in intestinal inflammation may play a key role in the pathogenesis of Crohn's disease. In particular, interleukin (IL)-23 may be a key mediator in chronic intestinal inflammation by inducing the differentiation of naïve CD4+ T cells into Th17, with the production of several pro-inflammatory cytokines. Furthermore, IL-23 induces interferon-γ (IFN- γ) production from activated T cells, a critical cytokine in innate and adaptive immunity against infections. Areas covered: We aim to review the available data from literature regarding the role of IL-23, with a more specific focus on the recent progresses in the therapeutic modulation of this cytokine...
January 9, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28066859/the-long-term-outcome-of-anti-tnf-alpha-therapy-in-perianal-crohn-s-disease
#2
J Rayen, T Currie, R B Gearry, F Frizelle, T Eglinton
BACKGROUND: The aim of the present study was to evaluate the long-term outcomes of anti-tumour necrosis factor alpha therapy in perianal Crohn's disease and identify factors predicting response to treatment. METHODS: Data from hospital clinical records and coding databases were retrospectively reviewed from a tertiary care hospital in Christchurch, New Zealand. The study included 75 adult patients with perianal Crohn's disease commenced on anti-tumour necrosis factor alpha therapy from January 2000 to December 2012...
January 9, 2017: Techniques in Coloproctology
https://www.readbyqxmd.com/read/28058028/hepatosplenic-t-cell-lymphoma-in-a-47-year-old-crohn-s-disease-patient-on-thiopurine-monotherapy
#3
Maartje M van de Meeberg, Lauranne A A P Derikx, Harm A M Sinnige, Peet Nooijen, D Lucette Schipper, Loes H C Nissen
Hepatosplenic T-cell lymphoma (HSTCL) is a rare non-Hodgkin lymphoma with a high mortality rate. Higher incidence is reported in patients with inflammatory bowel disease, specifically in male patients that are younger than 35 years, and have been treated with thiopurine and tumor necrosis factor (TNF)-α inhibitor combination therapy for over 2 years. In this case report we describe a 47-year-old patient with Crohn's disease (CD) who developed HSTCL after having been treated with thiopurine monotherapy for 14 years...
December 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28058018/factors-associated-with-surgery-in-patients-with-intra-abdominal-fistulizing-crohn-s-disease
#4
Shaul Yaari, Ariel Benson, Eyal Aviran, Naama Lev Cohain, Ran Oren, Jacob Sosna, Eran Israeli
AIM: To characterize radiological and clinical factors associated with subsequent surgical intervention in Crohn's disease (CD) patients with intra-abdominal fistulae. METHODS: From a cohort of 1244 CD patients seen over an eight year period (2006 to 2014), 126 patients were identified as having intra-abdominal fistulae, and included in the study. Baseline patient information was collected from the medical records. Imaging studies were assessed for: anatomic type and number of fistulae; diameter of the inflammatory conglomerate; length of diseased bowel; presence of a stricture with pre-stenotic dilatation; presence of an abscess; lymphadenopathy; and the degree of bowel enhancement...
December 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28038706/hepatosplenic-t-cell-lymphoma-arising-in-patients-with-immunodysregulatory-disorders-a-study-of-7-patients-who-did-not-receive-tumor-necrosis-factor-%C3%AE-inhibitor-therapy-and-literature-review
#5
Mariko Yabe, L Jeffrey Medeiros, Yahya Daneshbod, Masoud Davanlou, Carlos E Bueso-Ramos, Elisa J Moran, Ken H Young, Roberto N Miranda
Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive extranodal T-cell lymphoma that can arise in patients with underlying immune disorders. Others have suggested that tumor necrosis factor (TNF)-α inhibitor therapy for immune disorders increases the risk of HSTCL. To assess for a potential relationship between HSTCL and the use of TNF-α inhibitors, we searched for patients with HSTCL and underlying immune disorders at our institution. We identified 7 patients with a median age of 38 years. Five patients had Crohn disease, 1 ulcerative colitis, and 1 rheumatoid arthritis...
February 2017: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/28035633/infliximab-biosimilars-in-the-treatment-of-inflammatory-bowel-diseases-a-systematic-review
#6
REVIEW
Massimo Radin, Savino Sciascia, Dario Roccatello, Maria Jose Cuadrado
BACKGROUND: Biological therapies represent a fundamental innovation for the management of inflammatory bowel diseases (IBD). However, many biological originators have reached, or are about to reach, patent expiry and long-term therapy costs have become progressively unsustainable. CT-P13, a biosimilar of the anti-tumor necrosis factor (anti-TNF) monoclonal antibody infliximab, might represent a significant alternative to its originator, with the potential to decrease medical care costs and, therefore, become available to a large number of patients...
December 29, 2016: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/28028358/thiopurines-and-inflammatory-bowel-disease-current-evidence-and-a-historical-perspective
#7
REVIEW
Jordan E Axelrad, Abhik Roy, Garrett Lawlor, Burton Korelitz, Simon Lichtiger
The use of thiopurines in inflammatory bowel disease (IBD) has been examined in numerous prospective, controlled trials, with a majority demonstrating a clinical benefit. We conducted this review to describe the historical and current evidence in the use of thiopurines in IBD. A systematic search was performed on MEDLINE between 1965 and 2016 to identify studies on thiopurines in IBD. The most robust evidence for thiopurines in IBD includes induction of remission in combination with anti-tumor necrosis factor (anti-TNF) agents, and maintenance of remission and post-operative maintenance in Crohn's disease...
December 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27995633/infliximab-vs-adalimumab-in-crohn-s-disease-results-from-327-patients-in-an-australian-and-new-zealand-observational-cohort-study
#8
J D Doecke, F Hartnell, P Bampton, S Bell, G Mahy, Z Grover, P Lewindon, L V Jones, K Sewell, K Krishnaprasad, R Prosser, D Marr, J Fischer, G R Thomas, J V Tehan, N S Ding, S E Cooke, K Moss, A Sechi, P De Cruz, R Grafton, S J Connor, I C Lawrance, R B Gearry, J M Andrews, G L Radford-Smith
BACKGROUND: Maintenance anti-tumour necrosis factor-α (anti-TNFα) treatment for Crohn's disease is the standard of care for patients with an inadequate response to corticosteroids and immunomodulators. AIM: To compare the efficacy and safety of infliximab and adalimumab in clinical practice and assess the value of concomitant immunomodulator therapy. METHODS: We performed an observational cohort study in consecutive patients with Crohn's disease qualifying for anti-TNFα treatment in Australia and New Zealand between 2007 and 2011...
February 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27984399/accuracy-of-consecutive-fecal-calprotectin-measurements-to-predict-relapse-in-inflammatory-bowel-disease-patients-under-maintenance-with-anti-tnf-therapy-a-prospective-longitudinal-cohort-study
#9
Rocio Ferreiro-Iglesias, Manuel Barreiro-de Acosta, Aurelio Lorenzo-Gonzalez, Juan E Dominguez-Muñoz
BACKGROUND AND GOAL: Predicting relapse in inflammatory bowel disease (IBD) patients could allow early changes in therapy. We aimed at evaluating the accuracy of consecutive fecal calprotectin (FC) measurements to predict flares in IBD patients under maintenance treatment with anti-tumor necrosis factor (TNF) drugs. STUDY: A prospective longitudinal cohort study with 16-month follow-up period was designed. IBD patients in clinical remission for at least 6 months under anti-TNF therapy were included...
December 14, 2016: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/27959607/ustekinumab-as-induction-and-maintenance-therapy-for-crohn-s-disease
#10
RANDOMIZED CONTROLLED TRIAL
Brian G Feagan, William J Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R Friedman, Marion A Blank, Jewel Johanns, Long-Long Gao, Ye Miao, Omoniyi J Adedokun, Bruce E Sands, Stephen B Hanauer, Severine Vermeire, Stephan Targan, Subrata Ghosh, Willem J de Villiers, Jean-Frédéric Colombel, Zsolt Tulassay, Ursula Seidler, Bruce A Salzberg, Pierre Desreumaux, Scott D Lee, Edward V Loftus, Levinus A Dieleman, Seymour Katz, Paul Rutgeerts
Background Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy. Methods We randomly assigned patients to receive a single intravenous dose of ustekinumab (either 130 mg or approximately 6 mg per kilogram of body weight) or placebo in two induction trials. The UNITI-1 trial included 741 patients who met the criteria for primary or secondary nonresponse to tumor necrosis factor (TNF) antagonists or had unacceptable side effects...
November 17, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27958285/postoperative-complications-after-ileocecal-resection-in-crohn-s-disease-a-prospective-study-from-the-remind-group
#11
Mathurin Fumery, Philippe Seksik, Claire Auzolle, Nicolas Munoz-Bongrand, Jean-Marc Gornet, Gilles Boschetti, Eddy Cotte, Anthony Buisson, Anne Dubois, Benjamin Pariente, Philippe Zerbib, Najim Chafai, Carmen Stefanescu, Yves Panis, Philippe Marteau, Karine Pautrat, Charles Sabbagh, Jerome Filippi, Marc Chevrier, Pascal Houze, Xavier Jouven, Xavier Treton, Matthieu Allez
OBJECTIVES: We sought to determine the frequency of and risk factors for early (30-day) postoperative complications after ileocecal resection in a well-characterized, prospective cohort of Crohn's disease patients. METHODS: The REMIND group performed a nationwide study in 9 French university medical centers. Clinical-, biological-, surgical-, and treatment-related data on the 3 months before surgery were collected prospectively. Patients operated on between 1 September 2010 and 30 August 2014 were included...
December 13, 2016: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/27958281/evolution-after-anti-tnf-discontinuation-in-patients-with-inflammatory-bowel-disease-a-multicenter-long-term-follow-up-study
#12
M J Casanova, M Chaparro, V García-Sánchez, O Nantes, E Leo, M Rojas-Feria, A Jauregui-Amezaga, S García-López, J M Huguet, F Arguelles-Arias, M Aicart, I Marín-Jiménez, M Gómez-García, F Muñoz, M Esteve, L Bujanda, X Cortés, J Tosca, J R Pineda, M Mañosa, J Llaó, J Guardiola, I Pérez-Martínez, C Muñoz, Y González-Lama, J Hinojosa, J M Vázquez, M P Martinez-Montiel, G E Rodríguez, R Pajares, M F García-Sepulcre, A Hernández-Martínez, J L Pérez-Calle, B Beltrán, D Busquets, L Ramos, F Bermejo, J Barrio, M Barreiro-de Acosta, O Roncedo, X Calvet, D Hervías, F Gomollón, M Domínguez-Antonaya, G Alcaín, B Sicilia, C Dueñas, A Gutiérrez, R Lorente-Poyatos, M Domínguez, S Khorrami, C Muñoz, C Taxonera, A Rodríguez-Pérez, A Ponferrada, M Van Domselaar, M L Arias-Rivera, O Merino, E Castro, J M Marrero, M Martín-Arranz, B Botella, L Fernández-Salazar, D Monfort, V Opio, A García-Herola, M Menacho, P Ramírez-de la Piscina, D Ceballos, P Almela, M Navarro-Llavat, V Robles-Alonso, A B Vega-López, I Moraleja, M T Novella, C Castaño-Milla, A Sánchez-Torres, J M Benítez, C Rodríguez, L Castro, E Garrido, E Domènech, E García-Planella, J P Gisbert
OBJECTIVES: The aims of this study were to assess the risk of relapse after discontinuation of anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), to identify the factors associated with relapse, and to evaluate the overcome after retreatment with the same anti-TNF in those who relapsed. METHODS: This was a retrospective, observational, multicenter study. IBD patients who had been treated with anti-TNFs and in whom these drugs were discontinued after clinical remission was achieved were included...
January 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/27941197/-immune-mediated-inflammatory-diseases-and-accompanying-comorbidities
#13
Maria Majdan
Immune-Mediated Inflammatory Diseases (IMIDs) are a group of unrelated conditions that share common inflammatory pathways with immune dysregulation and imbalance in inflammatory cytokines. The aetiology of these conditions is unknown. IMIDs encompassing disorders as diverse as asthma, type 1 and 2 diabetes mellitus, inflammatory bowel diseases (IBD) Crohn disease and ulcerative colitis, rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis (Ps), psoriatic arthritis (PsA), uveitis, juvenile idiopathic arthritis (JIA)...
2016: Wiadomości Lekarskie: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/27939339/unusual-case-of-duodenobiliary-fistula-complicating-crohn-s-disease-successfully-treated-with-adalimumab
#14
Aya Hammami, Aida Ben Slama, Hanen Jaziri, Wafa Ben Ameur, Imed Ben Mansour, Ahlem Brahem, Salem Ajmi, Hela Jemni, Mehdi Ksiaa, Ali Jmaa
Crohn's disease (CD) is characterized by transmural inflammation of the gastrointestinal tract, which predisposes to the formation of fistula. Duodenal involvement occurs in less than 5% of cases and often leads to clinically relevant strictures. However, fistula formation in the duodenum is exceptional. Herein, we report an unusual case of duodenobiliary fistula due to CD occurring in a 65-year-old patient who was successfully treated by anti-tumor necrosis factor (TNF) agents. This case report highlights the efficacy of anti-TNF alpha agents in the treatment of a bilioenteric fistula because it increases the probability of clinical remission and mucosal healing and therefore reduces the need for surgical treatment which may be associated morbidity...
December 2016: Arab Journal of Gastroenterology: the Official Publication of the Pan-Arab Association of Gastroenterology
https://www.readbyqxmd.com/read/27933686/risk-of-incident-mycobacterium-tuberculosis-infection-in-patients-with-inflammatory-bowel-disease-a-nationwide-population-based-study-in-south-korea
#15
S N Hong, H J Kim, K H Kim, S-J Han, I M Ahn, H S Ahn
BACKGROUND: The low incidence of Mycobacterium tuberculosis infection and lack of adequate controls have prevented researchers from estimating tuberculosis (TB) risk in inflammatory bowel disease (IBD) patients. AIM: To evaluate the risk of incident TB among IBD patients. METHODS: Using the 2011-2013 data of the South Korean National Health Insurance (NHI) system, we calculated the incidence rates (IRs), standardised incidence ratio (SIR) and number needed to screen (NNS) for incident TB in IBD patients compared to the general population in terms of subtype, age, gender and IBD medications...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27933472/tumor-necrosis-factor-alpha-inhibitors-did-not-influence-postoperative-morbidity-after-elective-surgical-resections-in-crohn-s-disease
#16
Paulo Gustavo Kotze, Mansur Paulo Saab, Bárbara Saab, Lorete Maria da Silva Kotze, Marcia Olandoski, Lilian Vital Pinheiro, Carlos Augusto Real Martinez, Maria de Lourdes Setsuko Ayrizono, Daniela de Oliveira Magro, Claudio Saddy Rodrigues Coy
BACKGROUND: The real impact of anti-tumor necrosis alpha (TNF) therapy in postoperative complications after intestinal resections in Crohn's disease (CD) still needs to be determined. AIMS: To compare the postoperative complication rates after elective intestinal resections in CD patients, with or without previous exposure to anti-TNF therapy. METHODS: This was a retrospective and observational study, with elective intestinal resections for CD (emergency procedures were excluded)...
December 8, 2016: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/27931132/guillain-barr%C3%A3-syndrome-during-adalimumab-therapy-for-crohn%C3%A2-s-disease-coincidence-or-consequence
#17
Guilherme Grossi Lopes Cançado, Eduardo Garcia Vilela
We report the case of a 64-year-old patient diagnosed with extensive ileal Crohn´s disease who developed Guillain-Barré syndrome after starting biological therapy with adalimumab. Neurologic involvement associated with inflammatory bowel diseases is recognized as an extra-intestinal manifestation. After the breakthrough of antitumor necrosis factor alpha (anti-TNF-α) agents, an increasing number of cases of acute inflammatory demyelinating polyneuropathies have been reported; however, only one case has been described in a patient with Crohn´s disease...
December 8, 2016: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/27930408/vedolizumab-as-induction-and-maintenance-therapy-for-crohn-s-disease-in-patients-na%C3%A3-ve-to-or-who-have-failed-tumor-necrosis-factor-antagonist-therapy
#18
Bruce E Sands, William J Sandborn, Gert Van Assche, Milan Lukas, Jing Xu, Alexandra James, Brihad Abhyankar, Karen Lasch
BACKGROUND: Vedolizumab is a gut-selective α4β7 integrin antagonist for the treatment of moderately to severely active Crohn's disease (CD). Aims of this study were to characterize the efficacy and safety of vedolizumab induction and maintenance therapy in patients who were naïve to tumor necrosis factor-alpha (TNF-α) antagonist therapy (TNF-naïve) or who had discontinued TNF-α antagonist therapy because of inadequate response (i.e., primary nonresponse), loss of response, or intolerance (collectively classified as the TNF-failure population)...
January 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27925192/pathogenic-role-of-associated-adherent-invasive-escherichia-coli-in-crohn-s-disease
#19
Giuseppe Mazzarella, Angelica Perna, Angela Marano, Angela Lucariello, Vera Rotondi Aufiero, Raffaele Melina, Germano Guerra, Fabio Silvio Taccone, Gaetano Iaquinto, Antonio De Luca
Several lines of evidence suggest that adherent-invasive E. coli (AIEC) strains play an important role in Crohn's disease (CD). The objective of this study was to investigate the pathogenic role of two AIEC strains, LF82 and O83:H1, in CD patients. Organ cultures of colonic biopsies from patients were set up to assess the effects of LF82 and O83:H1 on the expression of CEACAM6, LAMP1, HLA-DR, ICAM1 by immunohistochemistry and of IL-8, IFNΓ and TNF-α genes by RT-PCR. Moreover, on Caco2 cells we analyzed the cell cycle, the expression of MGMT and DNMT1 genes and DNA damage induced by LF82 and O83:H1, by FACS, RT-PCR and DAPI staining, respectively...
December 7, 2016: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/27914457/tumor-necrosis-factor-and-lymphotoxin-in-regulation-of-intestinal-inflammation
#20
REVIEW
E O Gubernatorova, A V Tumanov
Ulcerative colitis and Crohn's disease are the major forms of inflammatory bowel disease. Cytokines of the tumor necrosis factor (TNF) family play an important role in the regulation of intestinal inflammation. In this review, we discuss the function of key cytokines of this family - TNF and lymphotoxin (LT) - in mucosal healing, IgA production, and in control of innate lymphoid cells (ILCs), novel regulators of mucosal homeostasis in the gut. TNF plays a central role in the pathogenesis of inflammatory bowel diseases (IBD)...
November 2016: Biochemistry. Biokhimii︠a︡
keyword
keyword
24145
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"